From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

H.C. Wainwright analyst Andres Y. Maldonado confirmed a Buy rating and a $75.00 price target on Corbus Pharmaceuticals (NASDAQ:CRBP), representing significant upside potential from the current price ...

The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee’s continued service with Mersana on each such vesting date. The RSU ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The U.S. Patent and Trademark Office has a history of attempting to challenge judicial decisions that the Office, usually for its own policy ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...